158 related articles for article (PubMed ID: 31409613)
1. The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.
Marzi L; Szabova L; Gordon M; Weaver Ohler Z; Sharan SK; Beshiri ML; Etemadi M; Murai J; Kelly K; Pommier Y
Clin Cancer Res; 2019 Oct; 25(20):6206-6216. PubMed ID: 31409613
[TBL] [Abstract][Full Text] [Related]
2. Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with
Yap TA; Kristeleit R; Michalarea V; Pettitt SJ; Lim JSJ; Carreira S; Roda D; Miller R; Riisnaes R; Miranda S; Figueiredo I; Rodrigues DN; Ward S; Matthews R; Parmar M; Turner A; Tunariu N; Chopra N; Gevensleben H; Turner NC; Ruddle R; Raynaud FI; Decordova S; Swales KE; Finneran L; Hall E; Rugman P; Lindemann JPO; Foxley A; Lord CJ; Banerji U; Plummer R; Basu B; Lopez JS; Drew Y; de Bono JS
Cancer Discov; 2020 Oct; 10(10):1528-1543. PubMed ID: 32532747
[TBL] [Abstract][Full Text] [Related]
3. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.
Patel AG; De Lorenzo SB; Flatten KS; Poirier GG; Kaufmann SH
Clin Cancer Res; 2012 Mar; 18(6):1655-62. PubMed ID: 22291137
[TBL] [Abstract][Full Text] [Related]
4. CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer.
Orhan E; Velazquez C; Tabet I; Fenou L; Rodier G; Orsetti B; Jacot W; Sardet C; Theillet C
Cancer Lett; 2024 May; 589():216820. PubMed ID: 38574883
[TBL] [Abstract][Full Text] [Related]
5. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in
Sun C; Fang Y; Yin J; Chen J; Ju Z; Zhang D; Chen X; Vellano CP; Jeong KJ; Ng PK; Eterovic AKB; Bhola NH; Lu Y; Westin SN; Grandis JR; Lin SY; Scott KL; Peng G; Brugge J; Mills GB
Sci Transl Med; 2017 May; 9(392):. PubMed ID: 28566428
[TBL] [Abstract][Full Text] [Related]
6. LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination-mediated DNA double strand break repair.
Chen L; Hou J; Zeng X; Guo Q; Deng M; Kloeber JA; Tu X; Zhao F; Wu Z; Huang J; Luo K; Kim W; Lou Z
Clin Transl Med; 2021 Mar; 11(3):e341. PubMed ID: 33784003
[TBL] [Abstract][Full Text] [Related]
7. Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic Opportunities.
Piombino C; Pipitone S; Tonni E; Mastrodomenico L; Oltrecolli M; Tchawa C; Matranga R; Roccabruna S; D'Agostino E; Pirola M; Bacchelli F; Baldessari C; Baschieri MC; Dominici M; Sabbatini R; Vitale MG
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731844
[TBL] [Abstract][Full Text] [Related]
8. LP-184, a Novel Acylfulvene Molecule, Exhibits Anticancer Activity against Diverse Solid Tumors with Homologous Recombination Deficiency.
Kulkarni A; Zhou J; Biyani N; Kathad U; Banerjee PP; Srivastava S; Prucsi Z; Solarczyk K; Bhatia K; Ewesuedo RB; Sharma P
Cancer Res Commun; 2024 May; 4(5):1199-1210. PubMed ID: 38630886
[TBL] [Abstract][Full Text] [Related]
9. Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency.
Li W; Gao L; Yi X; Shi S; Huang J; Shi L; Zhou X; Wu L; Ying J
Genomics Proteomics Bioinformatics; 2023 Oct; 21(5):962-975. PubMed ID: 36791952
[TBL] [Abstract][Full Text] [Related]
10. SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
Winkler C; Armenia J; Jones GN; Tobalina L; Sale MJ; Petreus T; Baird T; Serra V; Wang AT; Lau A; Garnett MJ; Jaaks P; Coker EA; Pierce AJ; O'Connor MJ; Leo E
Br J Cancer; 2021 Mar; 124(5):951-962. PubMed ID: 33339894
[TBL] [Abstract][Full Text] [Related]
11. Targeting HR Repair as a Synthetic Lethal Approach to Increase DNA Damage Sensitivity by a RAD52 Inhibitor in BRCA2-Deficient Cancer Cells.
Tseng WC; Chen CY; Chern CY; Wang CA; Lee WC; Chi YC; Cheng SF; Kuo YT; Chiu YC; Tseng ST; Lin PY; Liou SJ; Li YC; Chen CC
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922657
[TBL] [Abstract][Full Text] [Related]
12. NRDE2 deficiency impairs homologous recombination repair and sensitizes hepatocellular carcinoma to PARP inhibitors.
Wang Y; Liu X; Zuo X; Wang C; Zhang Z; Zhang H; Zeng T; Chen S; Liu M; Chen H; Song Q; Li Q; Yang C; Le Y; Xing J; Zhang H; An J; Jia W; Kang L; Zhang H; Xie H; Ye J; Wu T; He F; Zhang X; Li Y; Zhou G
Cell Genom; 2024 May; 4(5):100550. PubMed ID: 38697125
[TBL] [Abstract][Full Text] [Related]
13. A molecular glue RBM39-degrader induces synthetic lethality in cancer cells with homologous recombination repair deficiency.
Kohsaka S; Yagishita S; Shirai Y; Matsuno Y; Ueno T; Kojima S; Ikeuchi H; Ikegami M; Kitada R; Yoshioka KI; Toshimitsu K; Tabata K; Yokoi A; Doi T; Yamamoto N; Owa T; Hamada A; Mano H
NPJ Precis Oncol; 2024 May; 8(1):117. PubMed ID: 38789724
[TBL] [Abstract][Full Text] [Related]
14. Identification of Schlafen-11 as a Target of CD47 Signaling That Regulates Sensitivity to Ionizing Radiation and Topoisomerase Inhibitors.
Kaur S; Schwartz AL; Jordan DG; Soto-Pantoja DR; Kuo B; Elkahloun AG; Mathews Griner L; Thomas CJ; Ferrer M; Thomas A; Tang SW; Rajapakse VN; Pommier Y; Roberts DD
Front Oncol; 2019; 9():994. PubMed ID: 31632920
[TBL] [Abstract][Full Text] [Related]
15. CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines.
Rajapakse VN; Luna A; Yamade M; Loman L; Varma S; Sunshine M; Iorio F; Sousa FG; Elloumi F; Aladjem MI; Thomas A; Sander C; Kohn KW; Benes CH; Garnett M; Reinhold WC; Pommier Y
iScience; 2018 Dec; 10():247-264. PubMed ID: 30553813
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer.
Scattolin D; Maso AD; Ferro A; Frega S; Bonanno L; Guarneri V; Pasello G
Cancer Treat Rev; 2024 May; 128():102768. PubMed ID: 38797062
[TBL] [Abstract][Full Text] [Related]
17. PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
Nizialek E; Antonarakis ES
Cancer Manag Res; 2020; 12():8105-8114. PubMed ID: 32982407
[TBL] [Abstract][Full Text] [Related]
18. Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress.
Murai J; Zhang H; Pongor L; Tang SW; Jo U; Moribe F; Ma Y; Tomita M; Pommier Y
Cell Rep; 2020 Mar; 30(12):4137-4151.e6. PubMed ID: 32209474
[TBL] [Abstract][Full Text] [Related]
19. Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer.
Zhang S; Iyer S; Ran H; Dolgalev I; Gu S; Wei W; Foster CJR; Loomis CA; Olvera N; Dao F; Levine DA; Weinberg RA; Neel BG
Cancer Discov; 2021 Feb; 11(2):362-383. PubMed ID: 33158842
[TBL] [Abstract][Full Text] [Related]
20. Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib.
Bagnolini G; Milano D; Manerba M; Schipani F; Ortega JA; Gioia D; Falchi F; Balboni A; Farabegoli F; De Franco F; Robertson J; Pellicciari R; Pallavicini I; Peri S; Minucci S; Girotto S; Di Stefano G; Roberti M; Cavalli A
J Med Chem; 2020 Mar; 63(5):2588-2619. PubMed ID: 32037829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
